Efficacy and Safety of Quadruple-Drug Fixed-Dose Single-Pill Combination Therapy for Hypertension and Dyslipidemia: A Prospective, Multicenter, Observational Study

Highlights•QFDC therapy provides effective management for both hypertension and dyslipidemia. •QFDC with L/A/R/E successfully achieved target BP and LDL-C levels at 12 weeks. •Combination therapy showed a low rate of adverse events in real-world practice. •Simplified QFDC regimen reduces treatment c...

Full description

Saved in:
Bibliographic Details
Published inClinical therapeutics
Main Authors Park, Soohyung, MD, Park, Eun Jin, MD, PhD, Park, Moon-hwa, MD, Chu, Wonsang, MD, Lee, Dae-In, MD, Roh, Seung-Young, MD, PhD, Choi, Cheol Ung, MD, PhD, Kang, Dong Oh, MD, PhD
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 25.08.2025
Subjects
Internal Medicine
Hypertension
Rosuvastatin
Drug combinations
Losartan
Dyslipidemia
Ezetimibe
L/A/R/E
SBP
QFDC
DBP
AE
LDL-C
SAE
SADR
BP
ADR
Online AccessGet full text
ISSN0149-2918
1879-114X
1879-114X
DOI10.1016/j.clinthera.2025.07.023

Cover

More Information
Summary:Highlights•QFDC therapy provides effective management for both hypertension and dyslipidemia. •QFDC with L/A/R/E successfully achieved target BP and LDL-C levels at 12 weeks. •Combination therapy showed a low rate of adverse events in real-world practice. •Simplified QFDC regimen reduces treatment complexity, enhances patient adherence.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0149-2918
1879-114X
1879-114X
DOI:10.1016/j.clinthera.2025.07.023